$7.65
0.121.59%
Last update: Nov 11, 6:27 PM
BioCryst Pharmaceuticals Inc
BCRXNASDAQ
BioCryst Pharmaceuticals rose 5.8% from $7.23 to $7.65, behind the S&P 500's +9.8%. Its worst day was Sep 8 (−9.0%), and its low came Feb 5 at $6.24.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BioCryst Pharmaceuticals shares rose 9.3%, while the S&P 500 rose 0.1%.
+9.3% · S&P 500 +0.1%
BioCryst Pharmaceuticals closed at its lowest level of the year, 13.7% below where the year started.
Story events cover the past 12 months · Times ET
−2.8% · S&P 500 −1.2%
EPS of $0.06 missed the $0.07 estimate on $163.3M revenue (est. $150.5M); FY revenue guidance of $635.0M–$660.0M against the $641.3M consensus.
+4.6% · S&P 500 −0.6%
BioCryst Pharmaceuticals shares rose 13.1%, while the S&P 500 rose 1.0%.
+13.1%, the year's best day, on 20M shares, the year's heaviest volume · S&P 500 +1.0%
EPS of $0.14 beat the $0.10 estimate on $156.4M revenue (est. $152.2M); FY revenue guidance of $635.0M–$660.0M against the $648.7M consensus.
−2.2% · S&P 500 +1.4%
BioCryst Pharmaceuticals shares rose 7.7%, while the S&P 500 fell 0.0%.
+7.7% · S&P 500 0.0%
BioCryst Pharmaceuticals closed at its highest level of the year, 53.7% above where the year started.
+1.1% · S&P 500 −0.3%
EPS of $0.30 beat the $0.22 estimate on $218.3M revenue (est. $187.8M); FY revenue guidance of $690.0M–$715.0M against the $669.6M consensus.
+0.6% · S&P 500 −0.2%
BioCryst Pharmaceuticals shares fell 9.0%, while the S&P 500 fell 0.5%.
−9.0%, the year's worst day · S&P 500 −0.5%
EPS of $0.14 beat the $0.11 estimate on $180.3M revenue (est. $165.8M); FY revenue guidance of $715.0M–$730.0M against the $710.2M consensus.
−3.9% · S&P 500 +1.7%
Where it ended: a close of $7.65 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.10, revenue est. $166.2M).
Nothing in the past 12 months.
All BCRX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BCRX and SPY from Benzinga historical bars. Not investment advice.
